0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy ONLINE FIRST

Veronica J. Shi, MD1; Nemanja Rodic, MD, PhD1,2; Scott Gettinger, MD3; Jonathan S. Leventhal, MD1; Julia P. Neckman, MD1; Michael Girardi, MD1; Marcus Bosenberg, MD, PhD1,2; Jennifer N. Choi, MD4
[+] Author Affiliations
1Department of Dermatology, Yale School of Medicine, New Haven, Connecticut
2Department of Pathology, Yale School of Medicine, New Haven, Connecticut
3Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut
4Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Dermatol. Published online July 13, 2016. doi:10.1001/jamadermatol.2016.2226
Text Size: A A A
Published online

Importance  Antagonist antibodies to programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have shown remarkable activity in multiple tumor types. Recent US Food and Drug Administration approval of such agents for advanced melanoma, non–small cell lung cancer, and renal cell carcinoma has hastened the need to better characterize their unique toxicity profiles.

Objective  To provide a clinical and pathologic description of the lichenoid mucocutaneous adverse effects seen in patients receiving anti–PD-1/PD-L1 treatment.

Design, Setting, and Participants  Patients with advanced cancer who were referred to dermatology at Yale–New Haven Hospital, a tertiary care hospital, after developing cutaneous adverse effects while receiving an anti–PD-1 or PD-L1 antibody therapy either as monotherapy or in combination with another agent were identified. Medical records from 2010 to 2015 and available skin biopsy specimens were retrospectively reviewed.

Main Outcomes and Measures  Patient demographic characteristics, concurrent medications, therapeutic regimen, type of disease, previous oncologic therapies, clinical morphology of cutaneous lesions, treatment of rash, peripheral blood eosinophil count, tumor response, and skin histologic characteristics if biopsies were available.

Results  Patients were 13 men and 7 women, with a mean (range) age of 64 (46-86) years. The majority of cases (16 [80%]) had a clinical morphology consisting of erythematous papules with scale in a variety of distributions. Biopsies were available from 17 patients; 16 (94%) showed features of lichenoid interface dermatitis. Eighteen patients were treated with topical corticosteroids, and only 1 patient required discontinuation of anti–PD-1/PD-L1 therapy. Only 4 of 20 patients (20%) developed peripheral eosinophilia. Sixteen patients (80%) were concurrently taking medications that have been previously reported to cause lichenoid drug eruptions.

Conclusions and Relevance  Papular and nodular eruptions with scale, as well as mucosal erosions, with lichenoid features on histologic analysis were a distinct finding seen with anti–PD-1/PD-L1 therapies and were generally manageable with topical steroids. Concurrent medications may play a role in the development of this cutaneous adverse effect.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Figures

Place holder to copy figure label and caption
Figure 1.
Cutaneous Eruptions Consisting of Erythematous Papules With Scale Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

A, Small number of discrete scaly papules on the chest (patient number 4). B, Hypertrophic scaly papules and plaques on the lower extremity (patient number 12). C, Inflammation of and around existing seborrheic keratoses, in addition to new-onset scaly papules, on the back (patient number 14). D, Coalescent pseudovesiculated papules on the palm (patient number 6). E, Scaly, discrete papules and plaques on the palm (patient number 19). F, Numerous erosions on the penis, resembling erosive lichen planus (patient number 10).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Photomicrographs Showing Lichenoid Interface Dermatitis

A-C, Hematoxylin-eosin (H&E) staining, original magnification ×4, ×10, and ×20, respectively. Staining of lymphocytic infiltrate revealed the following immunoprofile: D, CD3-positive (both intradermal and intraepithelial lymphocytes); E, CD4-positive (intradermal lymphocytes); F, CD8-positive (intraepithelial lymphocytes); and G, CD20-negative.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

564 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();